Antengene's Recent Approval of XPOVIO® in Thailand
Antengene Corporation Limited, a distinguished global biopharmaceutical company, has reached a notable achievement with the approval of XPOVIO® (selinexor) by the Thailand Food and Drug Administration. This approval marks XPOVIO® as the first and only XPO1 inhibitor authorized for sale in the Thai market. The drug, aimed at treating multiple myeloma (MM), offers a fresh therapeutic option for patients who have run out of treatment options.
Indications for XPOVIO®
The indications for XPOVIO® in Thailand are particularly significant. It is designed to be used alongside bortezomib and dexamethasone for adult patients who have previously had treatment for multiple myeloma. Furthermore, it can also be used with dexamethasone for those who have seen their disease progress after at least four earlier therapies. This novel treatment has already been approved in several other markets across the Asia-Pacific region.
Broader Market Impact
Antengene's strategic vision includes bringing XPOVIO® to various regions worldwide. The drug has already been granted health insurance coverage in countries such as China, Australia, Singapore, and South Korea. This wide acceptance highlights the drug's potential effectiveness and impact on treating multiple myeloma, a category of blood cancers that occur due to the excessive growth of abnormal plasma cells.
Future Aspirations for XPOVIO®
As Antengene seeks to broaden its reach, they are working on launching XPOVIO® in Indonesia, with approval expected soon. This move is in response to the increasing demand for innovative cancer treatments in the ASEAN region, where demographic shifts are leading to greater healthcare requirements.
Innovative Mechanisms of Action
XPOVIO® functions through an unusual mechanism by inhibiting the export protein XPO1. This inhibition causes an accumulation of tumor suppressor proteins inside the cancer cells' nucleus, which ultimately hampers tumor growth. Additionally, XPOVIO® can activate glucocorticoid receptors, further boosting its effectiveness against certain tumors.
About Antengene
Antengene Corporation Limited, publicly traded on SEHK with the ticker 6996.HK, stands at the forefront of developing innovative cancer therapeutics. Its strong focus on research and development has established it as a key player in the biopharmaceutical field. The company's current pipeline includes an extensive range of cancer treatment assets, emphasizing its dedication to advancing cancer care across borders.
Frequently Asked Questions
What is XPOVIO® used for?
XPOVIO® (selinexor) is primarily intended for treating adult patients with multiple myeloma, especially those who haven't had success with several other therapies.
How does XPOVIO® work?
XPOVIO® functions by blocking the XPO1 protein, leading to an accumulation of tumor-suppressive proteins in the nucleus and triggering cell death in malignancies.
Where is XPOVIO® approved?
Currently, XPOVIO® is approved in several regions within the Asia-Pacific, including Thailand, mainland China, Australia, South Korea, and Singapore, among others.
What future plans does Antengene have for XPOVIO®?
Antengene intends to expand the approval of XPOVIO® into other markets like Indonesia and is exploring further treatment indications through various combination therapies.
How can patients access XPOVIO®?
Patients can obtain XPOVIO® through healthcare providers participating in national health insurance programs and from hospitals that include this treatment within their offerings.
